-
Je něco špatně v tomto záznamu ?
Survival advantage of Asian metastatic prostate cancer patients treated with external beam radiotherapy over other races/ethnicities
C. Würnschimmel, M. Wenzel, C. Collà Ruvolo, L. Nocera, Z. Tian, F. Saad, A. Briganti, SF. Shariat, P. Mandel, FKH. Chun, D. Tilki, M. Graefen, PI. Karakiewicz
Jazyk angličtina Země Německo
Typ dokumentu časopisecké články
Medline Complete (EBSCOhost) od 2000-02-01 do Před 1 rokem
Health & Medicine (ProQuest) od 1997-02-01 do Před 1 rokem
Odkazy
PubMed
33978812
DOI
10.1007/s00345-021-03720-7
Knihovny.cz E-zdroje
- MeSH
- Američané asijského původu statistika a číselné údaje MeSH
- běloši statistika a číselné údaje MeSH
- černoši nebo Afroameričané statistika a číselné údaje MeSH
- Hispánci a Latinoameričané statistika a číselné údaje MeSH
- karcinom etnologie mortalita radioterapie sekundární MeSH
- lidé středního věku MeSH
- lidé MeSH
- míra přežití MeSH
- mortalita etnologie MeSH
- nádory kostí etnologie mortalita sekundární MeSH
- nádory prostaty etnologie mortalita patologie radioterapie MeSH
- program SEER MeSH
- radioterapie * MeSH
- senioři MeSH
- tendenční skóre MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- Publikační typ
- časopisecké články MeSH
PURPOSE: To assess the effect of race/ethnicity in cancer-specific mortality (CSM) adjusted for other-cause mortality (OCM) in metastatic prostate cancer patients (mPCa) treated with external beam radiotherapy (EBRT) to the prostate. METHODS: We relied on the Surveillance, Epidemiology, and End Results (SEER) database to identify Caucasian, African-American, Hispanic/Latino and Asian mPCa patients treated by EBRT between 2004 and 2016. Cumulative incidence plots displayed CSM after adjustment for OCM according to race/ethnicity. Propensity score matching accounted for patient age, prostate-specific antigen, clinical T and N stages, Gleason Grade Groups and M1 substages. OCM adjusted multivariable analyses tested for differences in CSM in African-Americans, Hispanic/Latinos and Asians relative to Cauacasians. RESULTS: After 3:1 propensity score matching and OCM adjustment, Asians exhibited lower CSM at 60 and 120 months (48.2 and 60.0%, respectively) compared to Caucasians (66.7 and 79.4%, respectively, p < 0.001). In OCM adjusted multivariable analyses, Asian race/ethnicity was associated with lower CSM (HR 0.66, CI 0.52-0.83, p < 0.001). Conversely, African-American and Hispanic/Latino race/ethnicity did not affect CSM. OCM rates were comparable between examined races/ethnicities. CONCLUSION: In the setting of mPCa treated with EBRT, Asians exhibit lower CSM than Caucasians, African-Americans and Hispanic/Latinos. This observation may warrant consideration in prognostic stratification schemes for newly diagnosed mPCa patients.
Department of Urology 2nd Faculty of Medicine Charles University Prague Czech Republic
Department of Urology Comprehensive Cancer Center Medical University of Vienna Vienna Austria
Department of Urology University Hospital Frankfurt Frankfurt am Main Germany
Department of Urology University Hospital Hamburg Eppendorf Hamburg Germany
Department of Urology University of Texas Southwestern Dallas TX USA
Departments of Urology Weill Cornell Medical College New York NY USA
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22012183
- 003
- CZ-PrNML
- 005
- 20220506130218.0
- 007
- ta
- 008
- 220425s2021 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00345-021-03720-7 $2 doi
- 035 __
- $a (PubMed)33978812
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Würnschimmel, Christoph $u Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany. c.wuernschimmel@gmail.com $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada. c.wuernschimmel@gmail.com $1 https://orcid.org/0000000178914791
- 245 10
- $a Survival advantage of Asian metastatic prostate cancer patients treated with external beam radiotherapy over other races/ethnicities / $c C. Würnschimmel, M. Wenzel, C. Collà Ruvolo, L. Nocera, Z. Tian, F. Saad, A. Briganti, SF. Shariat, P. Mandel, FKH. Chun, D. Tilki, M. Graefen, PI. Karakiewicz
- 520 9_
- $a PURPOSE: To assess the effect of race/ethnicity in cancer-specific mortality (CSM) adjusted for other-cause mortality (OCM) in metastatic prostate cancer patients (mPCa) treated with external beam radiotherapy (EBRT) to the prostate. METHODS: We relied on the Surveillance, Epidemiology, and End Results (SEER) database to identify Caucasian, African-American, Hispanic/Latino and Asian mPCa patients treated by EBRT between 2004 and 2016. Cumulative incidence plots displayed CSM after adjustment for OCM according to race/ethnicity. Propensity score matching accounted for patient age, prostate-specific antigen, clinical T and N stages, Gleason Grade Groups and M1 substages. OCM adjusted multivariable analyses tested for differences in CSM in African-Americans, Hispanic/Latinos and Asians relative to Cauacasians. RESULTS: After 3:1 propensity score matching and OCM adjustment, Asians exhibited lower CSM at 60 and 120 months (48.2 and 60.0%, respectively) compared to Caucasians (66.7 and 79.4%, respectively, p < 0.001). In OCM adjusted multivariable analyses, Asian race/ethnicity was associated with lower CSM (HR 0.66, CI 0.52-0.83, p < 0.001). Conversely, African-American and Hispanic/Latino race/ethnicity did not affect CSM. OCM rates were comparable between examined races/ethnicities. CONCLUSION: In the setting of mPCa treated with EBRT, Asians exhibit lower CSM than Caucasians, African-Americans and Hispanic/Latinos. This observation may warrant consideration in prognostic stratification schemes for newly diagnosed mPCa patients.
- 650 _2
- $a černoši nebo Afroameričané $x statistika a číselné údaje $7 D001741
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a Američané asijského původu $x statistika a číselné údaje $7 D001213
- 650 _2
- $a nádory kostí $x etnologie $x mortalita $x sekundární $7 D001859
- 650 _2
- $a karcinom $x etnologie $x mortalita $x radioterapie $x sekundární $7 D002277
- 650 _2
- $a Hispánci a Latinoameričané $x statistika a číselné údaje $7 D006630
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a mortalita $x etnologie $7 D009026
- 650 _2
- $a tendenční skóre $7 D057216
- 650 _2
- $a nádory prostaty $x etnologie $x mortalita $x patologie $x radioterapie $7 D011471
- 650 12
- $a radioterapie $7 D011878
- 650 _2
- $a program SEER $7 D018426
- 650 _2
- $a míra přežití $7 D015996
- 650 _2
- $a běloši $x statistika a číselné údaje $7 D044465
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Wenzel, Mike $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada $u Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany
- 700 1_
- $a Collà Ruvolo, Claudia $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada $u Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples Federico II, Naples, Italy
- 700 1_
- $a Nocera, Luigi $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada $u Department of Urology and Division of Experimental Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy
- 700 1_
- $a Tian, Zhe $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada
- 700 1_
- $a Saad, Fred $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada
- 700 1_
- $a Briganti, Alberto $u Department of Urology and Division of Experimental Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy
- 700 1_
- $a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Departments of Urology, Weill Cornell Medical College, New York, NY, USA $u Department of Urology, University of Texas Southwestern, Dallas, TX, USA $u Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic $u Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia $u Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan
- 700 1_
- $a Mandel, Philipp $u Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany
- 700 1_
- $a Chun, Felix K H $u Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany
- 700 1_
- $a Tilki, Derya $u Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany $u Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany
- 700 1_
- $a Graefen, Markus $u Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany
- 700 1_
- $a Karakiewicz, Pierre I $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada
- 773 0_
- $w MED00004739 $t World journal of urology $x 1433-8726 $g Roč. 39, č. 10 (2021), s. 3781-3787
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33978812 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220425 $b ABA008
- 991 __
- $a 20220506130211 $b ABA008
- 999 __
- $a ok $b bmc $g 1789679 $s 1163384
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 39 $c 10 $d 3781-3787 $e 20210512 $i 1433-8726 $m World journal of urology $n World J Urol $x MED00004739
- LZP __
- $a Pubmed-20220425
